Oil prices turn lower as Bessent says U.S. may have Iran deal "today or tomorrow"

Several investment funds affiliated with Insight Holdings Group, collectively referred to as the Insight Entities, recently sold approximately $4.6 million worth of Class A Common Stock in Hinge Health, Inc. (NASDAQ:HNGE). The transactions, which occurred on June 16, 2026, involved the disposition of 65,581 shares at a weighted average price of $70.3596 per share. Individual sales within this period ranged from $70.01 to $70.62 per share.The timing of these sales comes as Hinge Health stock trades near its 52-week high of $70.72, following a remarkable 75% gain over the past year. According to InvestingPro analysis, the stock is currently trading close to its Fair Value. Investors seeking deeper insights can access the comprehensive Pro Research Report, available for HNGE and 1,400+ other US equities.

Prior to these sales, the Insight Entities converted 65,581 shares of Class B Common Stock into an equal number of Class A Common Stock. Each share of Class B Common Stock is convertible at any time at the option of the holder into one share of Class A Common Stock, as outlined in Hinge Health’s amended and restated certificate of incorporation. The Class B shares automatically converted into Class A shares upon the occurrence of certain events.

The sales were executed under a Rule 10b5-1 trading plan, which was adopted on August 20, 2025. The reporting owners, including Insight Venture Partners X, L.P., Insight Venture Partners X (Co-Investors), L.P., Insight Venture Partners (Cayman) X, L.P., and Insight Venture Partners (Delaware) X, L.P., are considered ten percent owners of Hinge Health. Insight Holdings Group, LLC and its affiliates manage these funds and maintain shared voting and dispositive power over the shares.

In other recent news, Hinge Health Inc has garnered attention following its Investor Day and Movement client conference, resulting in several updates from financial analysts. Canaccord has raised its price target for Hinge Health to $76, citing expectations of adding 4 to 5 million covered lives during the 2026 selling season. KeyBanc has also increased its price target to $90, highlighting new product offerings, including a surgical option through HingeSelect. Similarly, Truist Securities has adjusted its target to $85, expressing confidence in the company’s growth trajectory after attending the Analyst Day.

Citizens has maintained a Market Outperform rating with an $80 price target, reaffirming its positive outlook post-conference. Stifel reiterated its Buy rating and $79 target, focusing on the company’s expansion into surgical solutions and revised financial targets. These developments underscore Hinge Health’s strategic initiatives and the positive reception from the investment community.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Is your HNGE trade worth the risk?

Before you click "buy," know exactly where to set your stop-loss. Our Vision AI literally "sees" your HNGE chart and delivers a complete risk management plan—entry, stop-loss, and profit target—in under 60 seconds.
Protect your downside. Validate every trade. Invest smarter.